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ABSTRACT
Pentosan polysulphate is  an hepar in ahalogue which acts
v ia an ant i thrombin I t I  (AT I I l )  independent  pathway.  We
compared the ef fect  of  th is  drug to that  of  hepar in and
AT  I I f  i n fus ions  i n  AT  I I I  de f , i c i en t  pa t i en t s .  Fou r
pat ients wi th AT I I I  congeni ta l  def ic iency received on
three d i f ferent  occasions :  ( i )  an in fus lon of  human AT
rrr  concentrate (2o u/kg or  40 'J /kTl  r  ( i i )  a f l  in t ramus-
cular  i -n ject ion of  pentosan polysulphate (2 ng/kgl  '  ( i i i )
a  subcutaneous calc j -um hepar in in ject ion (1OO U/kg) .  ar
I I I  - in fus ion inhib i ts  the excessive thrombin qenerat ion
(46 Z of  inh ib i t ion)  observed in the p lasma of  AT I I I
def ic ient  pat ients dur ing at  least  12 hours,  but  does not
modi fy  the factor  Xa format ion.  On the contrary,  pentosan
potysulphate has a marked ef fect  on both thrombin (62 Z
of  inh ib i t ion)  and factor  Xa generat ion (57 Z of  inh ib i -
t i on )  s t i l l  p resen t  8  hou rs  a f t e r  i n j ec t i on .  Hepa r i n
in ject ion has the same ef fect ,  more pro longed,  as pento-
san polysulphate on thrombin generat ion but  is  not  so
ef fect ive on impair ing factor  Xa generat ion (27 Z of
inhib i t ion) .  The marked ef fect  of  pentosan polysulphate
on thrombin and factor  Xa generat ion in  these pat ients
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long term prophylax is  wi th antagonists  of  v i tamin K is  considered
to be at  th is  moment the t reatment  of  choice (2)  .  A wel l  contro l -
I ed  o ra l  an t i coagu la t i on  w i t l  as  a  ru le  ensu re  a  reasonab le  p ro -
phylax is  but  in  iome instances may be d i f f icu l t  or  impossib le.-surg ical  
in tervent ions,  ear ly  and late pregnancy and other  coul -
ter l ind icat i -ons such as I iver  d isease or  in test inal  malabsorpt ion
may  p reven t  i t s  use .  I n  t hese  cases ,  pa t i - en t s  can  be  t rea ted
w i th  AT  I I f  concen t ra te  i n fus ion  and /o r  hepa r i n .
Here we propose the adminls t rat ion of  pentosan polysul -
pha te  (Hemoc la r )  as  a  new fo rm o f  t r ea tmen t .  Pen tosan  po l ysu l -
pf ,ate is  an hepar in analogue widely used in Germany and France as
ln ant i thrombot ic  and ant i l ipaemic drug.  ] t  has a weak ant lcoa-
gulant  act iv i ty  compared to hepar in when measured by Act ivated
i a r t i a l  T h r o m b o p l a s l i n  T i m e  ( A . P . T . T . )  a s s a y  ( 3 , 4 ) ,  b u t  i n h i b i t s
markedly the th iombin and Xa generat ions by an AT I I I  independent
mechan i sm (5 )  .  we  tes ted  the  e f f i cacy  o f  t h i s  d rug  i n  AT  I l I
de f i c i en t  pa t i en t s  compared  to  AT  I I I  i n fus ion  and  hepa r i n  i n j ec -
t i on  (Ca tc ipa r i ne ) .  The  on l y  obse rved  abno rma l i t y  o f  haemos tas i s
in AT I I I  def ic ient  pat ients is  an increase of  thrombin genera-
t i on  (6  , 7 ,  wh i l e  t he  i n t r i ns i c  Aene ra t i on  o f  f ac to r  Xa  i s  no rma l .
However to prevent  thrombosis in  these pat ients wi th a
h igh  r i sk  o f  t h rombo-embo l i sm,  we  do  no t  j us t  t r y  t o  dec rease
the i r  excess i ve  t h romb in  f o rma t i on  bu t  a l so  t o  ac t  ea r l i e r  i n
the  coagu la t i on  cascade ,  by  impa i r i ng  t he  fac to r  Xa  fo rma t i on .
so we tested the ef fect  of  each t reatmenL by moni tor ing the ap-
pearance of  thrombin and act ivated factor  X in  b lood samples
i rom the pat ients at  regular  in tervals  af ter  adminis t rat ion of
t he  d rugs .
MATERIAL AND METHODS
I n  v i vo  s tud ies  :
Four pat ients ( three women, one man) wi th a congeni ta l
AT  I I I  de f i c i ency  ( t ype  I )  ,  on  t h ree  d i f f e ren t  occas ions  t  Ya -
ce l ved  ( i )  an  i n t ramuscu la r  i n j ec t i on  (2  ng /kg l  o f  pen tosan
po l ysu lpha te  (Hemoc la r ,  Labo ra to i re  C l i n -M idy ,  Pa r i s ,  F rance )  ;
t i i j  an  i n fus ion  o f  pu r i f i ed  human  AT  I I I  concen t ra te  f r om Cen-
t re  Reg iona l  de  T rans fus ion  Sangu ine ,  L i l l e ,  F rance  z  40  U /kg
for  three of  them and 20 U/kg for  the last  one,  th i -s  amount
be ing  h i s  usua l  p rophy lax i s  ;  t h i s  pa t i en t  was  neve r the less  i n -
c luded in the protocol  because the ef fect  of  AT I I I  in fus ion on
factor  Xa and thrombin generat ion was s imi lar  whatever  the dose
used  (4o  u / kg  o r  20  u / ks )  du r i ng  t he  f i r s t  12  hou rs  a f t e r  i n j ec -
t i o n  ;  ( i i i ) - a  s u b c u t a n e o u s  c a l c i u m  h e p a r i n  i n j e c t i o n  ( 1 O O  U / k g )
(Ca l c i pa r i ne ,  Labo ra to i re  Choay ,  Pa r i s ,  F rance )  i n  t h ree
n r { - i o n ] - c  a n l r z
Venous  b lood  samp les  we re  ob ta ined  ( i )  be fo re  (To )  and
a t  1  ( T 1 ) , 4  ( T 4 ) , 6  ( T 6 ) , 8  ( T 8 )  a n d  1 2  h o u r s  ( T 1 2 )  a f t e r  p e n -
tosan  po tysu lpha te  i n j ec t i on  and  m ixed  w i th  O .13  M t r i sod ium
c i t ra te  a t  a  ra t i o  o f  1  pa r t  c i t r a te  t o  9  pa r t s  b lood  ;  ( i l )  a t
! o ,  T 2 ,  T 4 ,  T 5 ,  T 8  a n d  T 1 2  a f t e r  h e p a r i n  i n j e c t i o n  t  ( i i i )  a t  T o ,
V o 1 . 3 7 ,  N o . 2
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12 '  16 and T1 2 afLer  AT r r r  in fus ion ;  the t ime of  the f i - rs t
samples af ter  hepar in ( tz1 and pentosan porysulphate (T l  )  in jec-
t ions were chosen,  according to the peak ef fect  observed i_n i
p rev ious  s tudy  (8 ) .  Samp les  we re  immed ia te l y  cen t r i f uged ,  f i r s t
a t  +  12oC du r i ng  10  m inu tes  a t  25oo  g ,  and  then  a t  *  i " c  du r i ng
30 minutes at  5ooo g.  The p lasma was then stored at  -  gooc in
p las t i c  t ubes  un t i l  t es ted .
Informed consent  of  the pat j -ents was obta ined. .
In  v i t ro s tudies :
In  a l l  the samples,  the fo l lowing tests were per formed :
Kaol in  cephal in  crot t ing Time,  prothrombin t ime,  factor  Xa
gene ra t i on  t es t ,  t h romb in  gene ra t i on  t es t ,  p l asma t i c  AT  I I I
de te rm ina t i on .
T h e  K a o l i n  c e p h a l i n  c l o t t i n g  T i m e  ( K . c . c . T . )  w a s  c a r r i e d
ou t  us ing  human  b ra in  cepha r i n  as  desc r i - bed  p rev i -ous l y  (9 ) .
P ro th romb in  T ime  (p .T . )  :  t o  O .1  m l  o f  t es t  p l asma  were
added  o .2  m l  o f  Neop las t j - n  (Labo ra to i re  s tago ,  F ranc - )  and  the
c lo t t i ng  t imes  reco rded .
Int r i_nsic  generat ion of  factor  Xa in p lasma :  1 vo1.  of
Rep t i l ase  (Labo ra to i re  s tago ,  F rance )  de f i b r i na ted  (20  p r  o f
Rept i lase/ml  p lasma) p late let  poor  p lasma was add.ed to 1 vol_.  of
cepho tes t  ( cepha l i n  p lus  e l l ag i c  ac id ,  Nyegaa rd  and  co ,  os1o ,
Norway) and 1 vor .  of  25 mM cac12.  The mj-xture was incubated at
37oc  i n  a  p las t i c  t ube .  A t  t ime  In te rva l s ,  t he  amoun t  o f  f ac to r
xa generated was determined by adding an ar iquot  of  the i_ncuba-
t ion mixture to a solut ion of  chromogenic substrate ,  s-2222( K a b i  D i a g n o s t i c a ,  S w e d e n ) ,  a s  d e s c r i b e a  p r e v i o u s l y  ( 5 ) .  T h e
absorbance was recorded at  4o5 nm. The in i t ia t  rate (AoD/minute)
was proport ional  to  the amount  of  factor  Xa generated.
Thrombin generat ion test  :  . l  vo l .  o f  undef ibr inated
plate let  poor  p lasma and 1 vol .  o f  human bra in cephal in  d i l_uted
in 25 rnM cac12 were mixed in a g lass test  tube at  37"c.  The
amount  of  thrombin generated was measured at  in tervals  by adding
o .1  m l  a l i quo ts  o f  t he  i ncuba t i - on  m ix tu re  t o  o .4  mr  o f  pu r i f i ed
human f ibr i -nogen (2 g/L l  prepared as previ -ously  descr ioea (1o)  .
Resu l t s  we re  exp ressed  i n  t h romb in  N . r .H .  un iLs  us ing  a  ca l i b ra -
t ion curve obta ined wi th ser ia l  d i lu t ions of  a s tandard thrombin
so lu t i on .
The amount  of  thrombin and factor  Xa generated were
quant i f ied as io l lowing :  the peak value (hx ;  *  = t ime in hours
af ter  drug in ject ion)  of  each generat ion curve was determined,
as wel l  as the d i - f ference between the peak value obta ined wi th
the.b lood sample taken before adminis t ia t ion of  the d. rug ho and
hx ( f igure 1 )  .  At  each t ime (x)  af ter  i -n ject ion,  the mein of  the
four  d i f ferences (ho -  hx)  obta ined for  Lhe four  pat ients was
calcurated.  For  each drug and at  each t ime the rat io  between the
A T  I I I  D E F I C I E N C Y
RESULTS
Charac ter i sti-cs ol, lhs at ients are sum@'
vitamin K
TABLE 1
CHARACTER]STICS OF THE PATIENTS
V o 1 . 3 7 ,  N o . 2
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mean of  these four  d i f ferences and the 
mean of  the four  values
o f h o w a s u s e d t o c a } c u l a t e t h e p e r c e n t a g e o f i n h i b i t i o n o f
thrombin and factor  Xa format ion '
A T f l l d e t e r m i n a t i o n s : A T I I ] h e p a r i n c o f a c t o r a c t i v i t y
was measured wi th- i - t r r ro*ogenic substrate,  
chromozym-TH (Labora-
to i re  S tago ,  r rance )  a "co rd ing  to  Ab i l dgaa rd  
(11 )  and  AT  I I I
ant igen level  * " " " " r "a by uanl j -n i  radia l  
immunodi f fus ion method
using p lates pui . f t " " "a f iom eehr ingwerke '  
Marburg '  West  Germany
(M-Part igen( lJ) .  Th;  AT I I I  levels  were expressed as 
a percentage
oi  t t tu  m6an-va1ue of  15 normal  p lasma'
C r o s s e d i m m u n o e l e c t r o p h o r e s i s : c r o s s e d i m m u n o e l e c t r o p h o -
res is  of  AT l r r  ; ; ;  ;er formed- by the two 
d imensional  immunoelec-
t ropho res i s  t ecnn i ; " ; - ; i  l au re l i  
( 12 \  mod i f i ed  by  sas  (13 )  i n
the  absence  o r  i n  t he  p resence  o f  hepa r i n  
i n . t he  f i r s t  e l ec t ro -
phoresis  tZZO ui i t " -  f r " i r . r i t t lml  buf  fe i ,  79 
uni ts  hepar in/ml
5 ; ; ; ; ; ; )  ; ; a - "= i ; ; -  2  z -  r abu i t  an r i -A r  f r r  
an t i se rum (Beh r i ns -
werke,  Marburgr-w6st  Germany) in  the second 
e lect rophoresis '
cha rac te r i s t i cso f  t he  AT  l I I  de f i c i ency  
o f  t he  f am i l y
have been puur is ieJ-pt- rz lot t "1v-  (J4)  '  F ive i :P: : : - " :^ : : : :
i#i i; ; i ; i l  i l ;-r"*" eb rrr level have surfered rrom severe
thrombo-embolic "pi""a"" 
; thev were not i l :]"9:9-:i-: l:-=::uv
because they had a long term prophylax is  
wi th antagonists  of
t  AT lrr
Pat ient 
tAct iv i tY
level  .  *
: A n t i g e n ' C . I - E .
:Type o f  AT r r r
.  
-  
Longen i ta l'  de f ic iencY
f rroo*lo.i" l'  epasodes  \
; ea t i en t  Famf lV j
FamilY 
' l :
P . D .  :
o . M .  :
eami lY 2
L \ . \ f .
7 1  4  z  N




'  5 2 2
- 4 6 6



















4 3 ? "
3 9 2
* Crossed Immuno-Electrophoresis
(wi th or  wi thout  hePar in)
----t
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Ef fec t s  o f  each  d rug  on  p ro th romb in  t ime  and  on  K .C .C .T .
The resul ts  are summarized in table 2.  fn  the laboratory,
t h e  n o r m a l  v a l u e s  o f  K . C . C . T .  a n d  P . T .  a r e  :  K . C . C . T .  =  6 2  t  8
s e c o n d s ,  P . T .  -  1 3  I  1  s e c o n d s .
TABLE 2
EFFECT OF EACH DRUG ON P .T .  AND K .C .C .T .
Hours post
in j  ect ion
Pentosan
P . T .  K . C . C . T .
(  seconds )
Hepar in
P . T .  K . C . C . T .
(  seconds )
A T  I I I
P . T .  K . C . C . T .












1 3 . 4
t J . f
1 3 . 6
t J . f ,






1 3 . 5
1 2 . 9







l 4 r . 3
1 4
t 5 . l
1 3 . O
The resul ts  are the means of  the values of  the pat i -ents.
Af ter  AT I f I  in ject ion no ef fect  on prothrombin t ime
could be observed.  Af ter  hepar in in ject ion no proJ-ongat ion of
the prothrombin time could be observed as the thromboplastin
(Neoplast in ,  Laborato i re Stago,  France)  conta ined protamin.  Af ter
pentosan polysulphate in ject ion,  the pro longat ion of  prothrombin
t ime t  hour  af ter  in ject ion was below 2 seconds.  There was no
e f f e c t  o n  K . C . C . T .  a f t e r  A T  I I I  i n f u s i o n .  A f t e r  h e p a r i n  i n j e c -
t ion,  there was a moderate pro longat ion (75 sec /65 sec)  of  the
K .C .C .T .  two  hou rs  a f t e r  i n j ec t i on .  A f te r  pen tosan  po l ysu lpha te
i -n ject ion,  there was a s l ight ly  h igher  pro longat ion of  the
K . C . C . T .  ( 8 7  s e c / 6 4  s e c )  t  h o u r  a f t e r  i n i e c t i o n .
Ef fect  on thrombin and factor  Xa generat ion tests
To i l lust rate the resul ts  and the method used to cal -
culate the inhib i t ion of  thrombin and factor  Xa generat ion,  the
data obta ined in one pat ient  af ter  in ject ion of  one d.rug (pen-
tosan polysulphate)  are shown on f j_gure 1.



















F I G .  1
E f fec t  o f  pen tosan  po l ysu tpha te  i n j ec t l on .on  
th romb in  gene -
ra t i on  (F ig :1A)  and -  f  ac to r  Xa  gene ra t i on  ^ (F ig '  
18 )  i - n  one
pa t i en t  ( pa i i en t  N .G ' )  :  con t r6 l  p l asma  + ' - -o  ;  
p l asma
o f t h e p a t i e n t a t T o ( H ; T 1 ( l h o u r a f t e r i n j e c t i o n )
y_-- ry  ,  , i -  (4  hours af  ter  in ject ionl  v- - -7 
;  T8 (8
hours af ter  in ject ion)  O--- -€ '  ho represents 
the peak
value of  t r re c i ive obta ined wi th the 
p lasma sample taken
before p" . rao" . , '  po lysulphate in ject ion.  i .  
hx represents
the peak value o-t tfte curve obti ined with 
the plasma
s a m p l e t a k e n x h o u r s ( x = 1 , 4 o r 8 h o u r s ) a f t e r i n j e c t i o n .
Ef fect  on thrombin generat ion test  
( f igure 2)  '
AT 1I1 in fus ion :  as we reported before 
(6)  '  the p lasma
o f  t he  AT  I I I  de f i c i en t  pa t i en t s  gLne ra ted  
nea r l y  tw i ce .3s  muc !
thrombin than normal  p lasma. AT l i l  in fus ion 
inhib i ted the exces-
s i v e t h r o m n i n g e n e r a t - i o n ( 4 6 z o f i n h i b i t i o n a t t 2 ) . T h i s i n h i -
b i t i on  was  s t i l l  e f f ec t i ve  a t  T1  2  
(18  ?  o f  i nh ib i t i on )  '  The
maximum inhib i t ion was the same for  the 
three pat ients in fused
wi th 40 U/kq AT r f r  t "  for  the pat ient  
in fused wi th 20 U/kq AT
I f I .
Hepar in in ject ion (only  1n three subjects)  
:  hepar in
in ject ion v/ r "  ro i i6wed by an inrr iu i t ion of  
thrombin format ion
01 ? of  inh in i l ion at  r -2)  that  remained 
important  at  T8 (42 Z\
bu t  has  subs ided  a t  T12 '
Pentosan polysulphate in ject lon-  :  a f ter  
pentosan poly-
sulphate in iect io i ,  i f r "  inh ib i t ion of  thrombin 
generat ion was
62  % aL  T1 ,  i t  pe rs i s ted  un t i l  T8  (15  ? )  bu t  
t he re  was  no  more
e f f e c t  a L  I 1 2 .
INCUBATION TIME (min.)
.  using a non parametr ic test of  Kruskar and warl is,  no
signif icat ive di f ference was found concerning the maximum effect
of the three drugs
V o ' | . 3 7 ,  N o . 2 AT I I I  DEFICIENCY
HOURS AFTER INJECTION
F I G . 2
Ef fect  on thrombin generat ion test  (mean values of
pat ients)  :  the columns indicate the percentage of
b i t ion (ho -  hx)  /ho of  thrombin format ion af ter  :




' i n i a n -
t i on  i  r  AT  l f f  i n fus ion . *  l im i t  va lues .
Ef fegt  on fqctor  Xa general io ,n tgst  ( f  igure 3)
Before in ject ion,  the p lasma of  the pat ients generated.
the same amount  of  factor  xa as normal  p lasml d id (noimal  sub-
j e c t s r  r r  =  1 3 ,  h o  =  0 . 1 9 8  J  o . o 9 4  ;  p a t i e n t s  b e f o r e  i n j e c t i o n ,
n  =  4 ,  1 1  p l a s m a t i c  s a m p l e s ,  h o  =  O , 2 2 j  r  O . O 1 5 ) .
The ef fect  of  the drugs on factor  xa generat ion are shown
on  f i gu re  3 .
AT r r r  in fus ion :  no ef fect  of  AT Trr  in fus ion on factor
Xa generat ion test  could be observed.
Hepar i r i  ln ject ion (only  in  three subjects)  :  two hours
af ter  in ject ion there was a moderate inhib i t ior i  o f  factor  xa
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Pentosan polysulphate in ject ion.  :  lhe, inhib i t ion 
of
f ac to r  Xa  fo rma t i on  (57  z )  was , t - "  i * po t tan t  
as . t he  i nh ib i t i on  o f
thrombin ror*r t iJ i - - " r ia  was st i r i -s ignie icant  
at  16 (42 z l  i  a t
T8 Qo Z)  the t "=, , f t "  are 
just  
" t - t f t t  
l imi t  o f  sensi t iv i ty  of
t he  t es t .
Using a non parametr ic  test  of  Kruskal  
and Wal l is '  the
maximum ef fects o i  t i r "  three ar"g"  
were-  s igni f icant ly  d i f ferent
(o .o1  <  p  <  o .o2 ; t . - e t t u "= t  o f  t f r e  sma t l  number  
o f  pa t i en t s '  a
pai red compar iso" 'b t t t " t t t  drugs could not  
be done'
F ] G .  3
Ef fect  on factor  Xa generat ion. test  
(mean values of
;h; -4 pat ients)  :  th6 columns indicate 
the percentage
oi-irrfribit iott (ho 
- trx) /ho of factor Xa formation
af  ter  :  @l pentosan polysulphate 
in j  ect ion i
=  hepa r i n - i n j ec t i b "  I  
r  AT  r r f  i n fus ion '







AT I I f  level
Af ter  hePar in
there was no change in
an increase of  AT f I I
and pentosan polysulphate inject ion'_at ' r rr  
level l  wfr i te there was of course
feve f  ( tab le  3 )  a f te r  AT l I I  in fus ion '
HOURS AFTER INJECTION
Vo '1 .37 ,  No .2 AT I I I  DEFICIENCY
TABLE 3
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r x
Plasmat ic
( x  =  t ime
A T  I I I
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T 6To ' I 1 2  z  I 2 4
4 0 '  3  6 5  1 5 5
:  ' l  z  52  t  72
1 2 9 1 1 7
The resul ts  obta ined af ter
means of  the values of  the
infus ion of  40
three sub- i  ects .
U /kg  AT  I I I  a re  t he
D I S C U S S I O N
Pat ien ts  w i t h  congen i t a l  AT  I I I  de f i c i ency  su f fe r  o f  r e -
current  thromboembol ism. Acute thrombo-embol ic  episodes are
t rea ted  by  hepa r i n  and  AT  I I I  concen t ra te  j _n fus ion  (15 ) .
In the prevent ion of  thrombosis,  t reatment  wi th ora l  an-
t i coagu l -n t  i s  h igh l y  e f f ec t i ve  (2 )  bu t  i s  no t  a lways  su i_ tab le
(p regnancy ,  i n tes t i na l  ma labso rp t i - on ,  su rge ry . . . )  .  f n  t hese
c i r cums tances ,  i t  cou ld  be  theo re t i ca l r y  i n te res t i ng  t o  use  pen -
tosan polysulphate ;  th is  drug,  as hepar i_n,  inh ib i ts  the forma-
t ion of  factor  Xa and thrombin but  exer ts  i ts  ef fect  by an AT rr r
independent  mechanj-sm and appeared to be j -n v i t ro,  in  the absence
of  AT r r r '  about  twice as potent  as hepar i -n when compared on a
we igh t  bas i s  (5 )  .
So ,  we  s tud ied  the  e f f ec t  o f  pen tosan  po l ysu lpha te  i n j ec -
t i on  i n  4  pa t i en t s  w i t h  AT  I I I  congen i t a l  de f i c i ency  ( t ype  I )
and compared i t  to  the ef fects of  AT r r r  concentrate in fus ion
and hepar in in ject ion.  The amount  of  in jected drugs was chosen
according to the usual  prophylact ic  posology used for  example in
su rge ry  (16 ,17 l ,  .  T t  i s  we l l  known  tha t  t n -e  p lasma  o f  t he  AT  I I I
def ic ient  pat ients generates more thrombin than normar p lasma
(6 ,7 )  .  We  found  i n  t h i s  s tudy  tha t  t he  i n t r i ns i c  gene ra l i on  o f
factor  Xa is  normal  in  these pat ients.  This 1s probably due to
the fact  that  factor  Xa when bound to phosphol ip ids in  the
p resence  o f  f ac to r  V  i s  p ro tec ted  f rom inh ib i t i on  by  AT  I I I  ( 19 ,
19)  and we can speculate that  i t  must  be the same for  factor  rXa
when bound to phosphol ip id.
In pat ients wi th a h igh r j_sk of  thrombosis j_ t  could be
of  in terest  to  t ry  wi th a prophylact ic  t reatment ,  not  only  to
br ing back to normal  thei r  excessive generat ion of  thrombin but
a l so  t o  ac t  ea r r i e r  i n  t he  coagu la t i on  cascad .e .  r t  i s  t he  reason
why we decided to est imate the ef fects of  the three drugs by
moni tor ing thrombin and factor  xa generat ion.AT rr r  in fus ion
inhib i ts  the excessive thrombj-n generat ion (46 z inhib i t ion at
T2  a f t e r  i n j ec t i on  and  s t i l l  18  ?  i nh ib i t i on  a t  T . l 2 ) ,  bu t  does
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not modify the factor Xa formation ;  
on the contrary '  pentosan
rrolvsulphate has a marked erteci-on'both 
thrombin rc2 Z inhibi-
i r io i , t  and factot i t -  generat ion 
(57 z inhibi t ion) st i l l  present
at T8. Heparin i" ; : . i ; ; ; "r . ,"=-;r"  
same ef f  ect as pentosan poly-
sulphate on throi i i ; ; " ; ; ; i t ; ; ! i ""- tzr 
? inhibi t ion) but is not so
e f f e c t i v e o n r m p a i r i n g f a c t o r X a . g e n e r a t i o n ! 2 J z i n h i b i t i o n ) .
The more i*portai l - . i i . . t  ot  p" i t3=.t t  
pory=nrphate compared to
heparin in j_nnioi [ ing tactor x" 
- i " i* i i ""-  
in Ar I f I  def ic ient
prasma is in n"; ; ' ; ; ; " . i l ""1-tr i th-. ; ;  
result  obtained in vi t ro rn
previous =tuaieJ- ( ; ; ' ; ; ; " i l "  ; i ; " ; t  on thrombin 
senerat ion test
is more prolongea't i t " t  heparin 
than after pentolan polysulphate
in jec t ion .  The ; ;  ; ; ; l " i t ' L io "  has  
no  e f fec t  on  the  K 'c 'c 'T"
After heparin ""a 
p""t"sin pofysulphate inject ion there 
r 's a '
s l igh t  p ro longa l io i - '  o f  the  K 'c 'c ' r "  
'  A I1  the  resu l ts  were  s iml la r
i_n rhe pat ienrs l l "u.Lr =t,rai"a 
i r* i r i "= despite sl ight ly di f fe-
rent level:  
; : " t t" i i l "nrr" .e prophyracr ic_ rrearment 
in Ar rr l -
congenital-  aer ic iei ' ly i^ ' r ' t "  ot tr"S"t lcoagurat lon 
is not sui tabler
is st i l l  a i"" t ," !JEl- ' t r - ' "  use of heparin 
does'  not look loqical
because i t  needs the prese"t t  ol- i r  
rr f  to be quite effect ive i
moreover rrepari i  J"t t ! t """  the ievel 
of  prasmai ic ar rrr  (20)
even when 9i.r"' '""ii""itt"ot"tv 15ii' 
rrt:--" is the reason why some
physicians pretel_l f te comuinat ion 
of subcutaneous heparin and
AT r r r  concencra tes  Q2\ .  no t t "J t  
i ;  ; ; ;  s tudy '  hepar in  a lone '  
a t
the doses lr t"a,* i I !  t -*ott  pt" i""g"d'  ?f f : : ! , -"n ' t r te- 
inhibi t ion of
thrombin formation'  Moreover sinc6 
this work was completed'
coutan t  .na  "o i i ' -  
i zz l  and Van-but ten  and co l l  
'  Q4)  have repor -
ted that heparrn is rapidty and 
p" i t iuf fy.  inac-t ivated during
blood sampl ing' ;^ i ;" ; - ; ' ' ' l i iptaleiets 
agents are added to the
anricoagurant sl iJ; ; ;" :  rrre-reroie 
trre iui t i tv of  heparin in in-
hibir ing rra and Xa generat ion"i !pJ;"4. i"  
t i t i "  paper- is probably
underest imated 
-r" l r ,  
in extent ana'aurat ion. other authors 
preler
to  use  AT f r f  . f " tu* t i t tes  a tone 
(25 \  ;  these in fus ions  o f  AT r r r
concentrates result  in a pott ' ' l i t i  
r isk of t ransmit t ing hepat i t ls
t o p a t i e n t s ( : 6 l ' M o r e o v e r o u r - r e s " t t s i n d i c a t e t h a t i n f u s i o n o f
AT 1I1 concentrates does not inrr iui t  
factor Xa formation, wbi le
pentosan poay= ' ' ' i i t l t " -a " "= '  - r r reore t ica l l y '  
in  a l l  pa t ien ts '  Pre-
vent ion of thrombin formatio". i "- i  
more iogical  prophylact ic
measure than thrombin scav.ngi i ]  lZi l - ;  
t f t6retor-e pentosan poly-
sulphate t t . . t* t" l  looks r ika ;" t ; ; iq" i  
i t ta trr tct lve al ternat ive
for prevent ing- ' -Lrrrombosj-s in er rr i  
aet ic ient pat ients '  However
there is as V"t-"o-"t"ay q{ t f t"  ei i "ct  
of  pentosan polysulphate
during pregnancy that woula " i iot  
to assert  i ts innocuity for
the foetu".  t , , i tntr  studies are necessary 
to establ ish the thera-
peut ic range, l ; : - to deterrni""  rr t" t  
doslsgive adequate thrombo-
sis preverr. to, t**I i f 'o"t  " t t t=ing 
bleeding compl icat ions'
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